Skip to content

Trial · Interventional

Status unknownPhase 4Registry data

Changes of Bone Metabolic Markers and Bone Mineral Density After Denosumab and/or Teriparatide Treatment in Japanese Osteoporotic Patients

NCTNCT02156960 (opens ClinicalTrials.gov in a new tab)Other idDeno-PTH2365
Open at ClinicalTrials.govAsk about this trial

Overview

Status
Status unknown
Phase
Phase 4
Enrollment
100 participants (estimated)
Sponsor
Shinshu University · Other
Design
Allocation not applicable · Open label (no masking)
Countries
1 country

Japan

Start
May 2014
Primary completion
May 2015
Completion
Nov 2022 (estimated)
First posted
5 Jun 2014 (estimated)
Last update posted
22 Oct 2020
Conditions
Osteoporosis

Timeline

1 trial

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
20142016201820202022
  1. Ph 4

    Changes of Bone Metabolic Markers and Bone Mineral Density After Denosumab and/or Teriparatide Treatment in Japanese Osteoporotic Patients

    NCT02156960

    May 2014 to est. Nov 2022

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

It has not been well known about the changes of bone metabolic markers, bone mineral density and other bone-related markers after teriparatide and/or denosumab treatment in Japanese osteoporotic patients.

Interventions

  • Denosumab treatment in osteoporotic patientsDrug
  • Teriparatide treatment in osteoporotic patientsDrug
  • Denosumab and teriparatide treatment in osteoporotic patientsDrug

Arms1

  • Experimental

    Denosumab and/or teriparatide treatment

    Denosumab and/or teriparatide treatment in osteoporotic patients

Primary outcomes1

Outcomes the sponsor listed as primary.

  1. Changes of bone mineral density

    Time frame · every 4-6 months

    Registry description

    Bone mineral density will be examined every 4-6 months to evaluate the suitability of the drug.

Secondary outcomes(1)

  1. Changes of bone turnover markers

    Time frame · every 3-6 months

    Registry description

    Bone turnover markers will be examined every 3-6 months to evaluate the suitability of the drug.

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

No results are posted for this trial.

A trial that is still running, or that stopped early, may post results later.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies0

Studies that cite this trial.

No study cites this trial.

Other registry references

References listed at the registry that are not in PepBank. They link to PubMed.

  • DerivedNakamura Y, Kamimura M, Ikegami S, Mukaiyama K, Uchiyama S, Taguchi A, Kato H. Changes in serum vitamin D and PTH values using denosumab with or without bisphosphonate pre-treatment in osteoporotic patients: a short-term study. BMC Endocr Disord. 2015 Dec 15;15:81. doi: 10.1186/s12902-015-0077-3. PMID 26666998

Eligibility

Who could join, as posted.

Sex
All
Age
from 1 Year up to 120 Years
Healthy volunteers
Accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: * Osteoporotic patients Exclusion Criteria: * none

PepBank is a research reference. Talk to a doctor before you use any peptide.